Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript
Fulgent Genetics, Inc. ( FLGT ) UBS Global Healthcare Conference 2025 November 10, 2025 5:00 PM EST Company Participants Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lu Li - UBS Investment Bank, Research Division Presentation Lu Li UBS Investment Bank, Research Division Great. Well, our next session is the management team from Fulgent Genetics.
Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript
Fulgent Genetics, Inc. ( FLGT ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Lu Li - UBS Investment Bank, Research Division David Westenberg - Piper Sandler & Co., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Greetings, and welcome to the Fulgent Genetics Q3 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Brandon Perthuis - Chief Commercial Officer Ming Hsieh - Chairman & CEO Paul Kim - Chief Financial Officer Conference Call Participants Andrew Harris Cooper - Raymond James & Associates, Inc., Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Lu Li - UBS Investment Bank, Research Division Lauren Sloane - The Blueshirt Group, LLC Operator Greetings, and welcome to the Fulgent Genetics Q2 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.23 per share. This compares to earnings of $0.15 per share a year ago.
Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.01 per share a year ago.
Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a significant undervaluation. However, nothing is cheap for no reason; the company is not making money and won't for a while.
Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - CFO Conference Call Participants David Westenberg - Piper Sandler Lu Li - UBS Andrew Cooper - Raymond James Operator Greetings and welcome to the Fulgent Genetics Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Fulgent Genetics Revenue Tops Estimates
Laboratory services and therapeutic development specialist Fulgent Genetics (FLGT 0.53%) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. 28, the company reported adjusted EPS of $0.04, outstripping expectations of a $0.12 per-share loss.
Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $0.28 per share a year ago.
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
Fulgent Genetics (FLGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
